0
0
0
0
1
2
3
$0
Is Charles River Laboratories solid or fragile? The Finex Financial Health Scanner reads CRL's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $4.0B |
|---|---|
| Net income | -$144.3M |
| Operating margin | 0.6% |
| Net margin | -3.6% |
| Cash and investments | $213.8M |
| Total debt | $2.1B |
| Free cash flow | $443.2M |
| Revenue growth (1 year) | -0.9% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.